Global Biopharmaceutical Contract Manufacturing Market was estimated to be worth roughly US$ 9.3 Billion in 2022 and is expected to grow at a CAGR of 10.5% to reach US$ 18.7 billion by 2029.
A few benefits provided by biopharmaceutical manufacturing businesses include access to pricey technologies, a shorter overall time to market investment for new pharmaceuticals, and increased flexibility. Several multinational corporations have outsourced their biopharmaceutical production operations as a result of these factors. When a biopharmaceutical company’s internal production capacity is restricted, contract manufacturing for the biopharmaceutical industry is highly recommended.
Pharmaceutical companies prefer not to take financial risks when formulating the final dose of medicines because they primarily concentrate on their core competencies. This is likely to hasten the growth of the global biopharmaceutical contract manufacturing market, which is projected to reach a value of US$18.7 billion by 2029, over the forecast period.
Act Now: Gain Exclusive Insights into the Rising Market Value of the Biopharmaceutical Contract Manufacturing Market Download Our Sample Report! @ https://www.futuremarketinsights.com/reports/sample/rep-gb-2982
Regional Insights:
The U.S. dominates the North American region with a total market share of 91.0% in 2021 and is projected to continue experiencing high growth throughout the forecast period.
Germany is set to exhibit a CAGR of over 11.5% in the European biopharmaceutical contract manufacturing market during the forecast period. In this region, the next generation therapy market is believed to be driven by biological treatment options compared to the pharmaceutical option.
China holds 34.8% share in the East Asia market in 2021 and is projected to increase at a CAGR rate of 13.5% during the forecast period. The growth of the biopharmaceutical contract manufacturing market in the country is growing because, most of the pharma and biopharma companies are focusing to capitalize on the growth.
Asia Pacific is gaining attention among manufacturers for biologics production at reduced manufacturing cost. Emerging regions offering greater profit margins are major focus points for biopharmaceutical contract manufacturing, globally.”
Empower Your Decision-Making with Insights from Experts. @
https://www.futuremarketinsights.com/ask-question/rep-gb-2982
Key Takeaways of Biopharmaceutical Contract Manufacturing Market Study
- Although microbial-based platforms are abundantly used for the production of pharmaceuticals, mammalian-based cell culture is expected to gain traction during the forecast period, owing to higher efficiency and increasing demand.
- In terms of product type, monoclonal antibodies currently hold a larger share of the biopharmaceutical contract manufacturing market, due to their superior efficacy as well as increasing adoption for the treatment of chronic diseases.
- North America is anticipated to be the most lucrative region in the global biopharmaceutical contract manufacturing market, offering growth opportunities to market players.
- The commercial application of biopharmaceutical contract manufacturing is expected to contribute a higher share as compared to clinical application by the end of 2029.
Key Market Players:
- Catalent Inc.
- Lonza Group Ag
- Patheon N.V. (Thermo Fisher Scientific Inc.)
- Abzena Plc.
- Sandoz International GmbH (Novartis AG)
- Fujifilm Diosynth Biotechnologies (FUJIFILM Holdings)
- Baxter Pharmaceutical Solutions LLC (Baxter Inc.)
- AbbVie Contract Manufacturing (AbbVie Inc.)
- Samsung Biologics Co. Ltd.
- ProBioGen AG
- Pfizer Centre Source Ltd (Pfizer Inc.)
- Novasep
- Biomeva GmbH
- Kbi Biopharma Inc
- Rentschler Biotechnologie GmbH
- Ajinomoto Althea Inc. (Ajinomoto Co., Inc.)
Unlock Exquisite Customization and Save Your Path to Personalized Perfection. @
https://www.futuremarketinsights.com/customization-available/rep-gb-2982
Key Market Segments Covered in Biopharmaceutical Contract Manufacturing Industry Research:
By Platform Type:
- Mammalian Based
- Microbial Based
By Product Type:
- Monoclonal Antibodies
- Recombinant Protein
- Vaccine
- Insulin
- Growth factor
- Interferons
- Others
By Application Type:
- Clinical
- Commercial
By Therapeutic Area Type:
- Autoimmune Diseases
- Oncology
- Metabolic Diseases
- Ophthalmology
- Cardiovascular Diseases
- Infectious Diseases
- Neurology
- Respiratory Disorders
- Others
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube